Context Therapeutics Inc

Research Context Therapeutics Inc (CNTX) on Bullrun: market cap USD 53.02M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCNTX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 53.02M
• Financial periodFY2025
• Net income-USD 36.12M
• Free cash flow-USD 26.42M

Valuation Snapshot

latest market cap is USD 53.02M.

About Context Therapeutics Inc

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.

Frequently asked questions

What is Context Therapeutics Inc's market cap?

Context Therapeutics Inc's market capitalization is USD 53.02M.

What does Context Therapeutics Inc do?

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors.